Why the study?
Cardiovascular autonomic neuropathy is a common and severe complication of diabetes, making timely diagnosis clinically important.
Does the combination of COMPASS 31 and HRV improve the diagnostic performance for cardiovascular autonomic neuropathy in patients with type 2 diabetes?
Population
103 hospitalized subjects with type 2 diabetes
Comparison
COMPASS 31 combined with HRV vs CARTs reference standard
Design
Diagnostic study
Key result
Combining the COMPASS 31 score with HRV indices (SDNN and LF) identified cardiovascular autonomic neuropathy in type 2 diabetes with an AUC of 0.958, 90.7% sensitivity, and 86.7% specificity.
Authors
Loading...
May support combined COMPASS 31-HRV use for CAN screening in diabetes; leaves open need for prospective validation before practice change.
Cross-Sectional (n=103)
Does the combination of COMPASS 31 and HRV improve the diagnostic performance for cardiovascular autonomic neuropathy in patients with type 2 diabetes?
Effect estimate: AUC 0.958
Combining the COMPASS 31 symptom score with heart rate variability indices (SDNN and LF) provides high diagnostic accuracy for cardiovascular autonomic neuropathy in patients with type 2 diabetes.
Zhang et al. (2020) conducted a cross-sectional in Type 2 diabetes with suspected cardiovascular autonomic neuropathy (n=103). Combination of COMPASS 31 score and HRV indices (SDNN and LF) vs. Individual tests (COMPASS 31 or HRV alone) was evaluated on Diagnosis of cardiovascular autonomic neuropathy (CAN) (AUC 0.958). Combining the COMPASS 31 score with HRV indices (SDNN and LF) identified cardiovascular autonomic neuropathy in type 2 diabetes with an AUC of 0.958, 90.7% sensitivity, and 86.7% specificity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: